Dr. Khorana Discusses Long-Term Tinzaparin Versus Warfarin in the CATCH Study
Alok Khorana, MD, discusses the long-term impacts of tinzaparin versus warfarin, as well as clinical predictors of recurrent venous thromboembolism (VTE) in cancer patients, in the CATCH study.
The CATCH study is a worldwide, randomized clinical trial of 900 patients with a malignancy and VTE. Half received the low- molecular-weight heparin tinzaparin, and the other half received warfarin. The primary outcome was to determine whether tinzaparin was superior to warfarin, in terms of reducing the risk of recurrent VTE, says Khorana.
The study results showed that tinzaparin was indeed superior; it was associated with less bleeding as well.
Alok Khorana, MD, medical oncologist, Cleveland Clinic, discusses the long-term impacts of tinzaparin versus warfarin, as well as clinical predictors of recurrent venous thromboembolism (VTE) in cancer patients, in the CATCH study.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
